Disclosed herein, inter alia, are compositions and methods useful for inhibiting reticulon 4 (RTN4).

The invention relates to a method for synthesis of 1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]piperazine in the presence of a strong base.

The invention relates to a method for synthesis of 1-[2-(2,4-Dimethyl-phenylsulfanyl)-phenyl]piperazine in the presence of a strong base.

Described herein are neuroactive steroids of the Formula (I); or a pharmaceutically acceptable salt thereof, wherein, R.sup.1, R.sup.2a, R.sup.2b, R.sup.3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

##STR00001##

Described herein are neuroactive steroids of the Formula (I); or a pharmaceutically acceptable salt thereof, wherein, R.sup.1, R.sup.2a, R.sup.2b, R.sup.3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

##STR00001##

A compound having a structure of Formula I,

##STR00001##

is provided. In Formula I, Z.sup.1 to Z.sup.16 are each CR or N; three consecutive ones of Z.sup.1 to Z.sup.16 within the same ring cannot be N; each R is independently a hydrogen or a substituent selected from a variety of substituents; at least one R includes and electron donor substituent; at least one R includes an electron acceptor substituent; and any two Rs on the same ring can be joined or fused together to form a ring. Organic light emitting devices, consumer products, formulations, and chemical structures containing the compounds are also disclosed.

A compound having a structure of Formula I,

##STR00001##

is provided. In Formula I, Z.sup.1 to Z.sup.16 are each CR or N; three consecutive ones of Z.sup.1 to Z.sup.16 within the same ring cannot be N; each R is independently a hydrogen or a substituent selected from a variety of substituents; at least one R includes and electron donor substituent; at least one R includes an electron acceptor substituent; and any two Rs on the same ring can be joined or fused together to form a ring. Organic light emitting devices, consumer products, formulations, and chemical structures containing the compounds are also disclosed.

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.